Meeder Asset Management Inc Aeglea Bio Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$4.01 - $11.04 $874 - $2,406	-218 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.51 - $8.48 $3,460 - $8,361	-986 Reduced 81.89%	218 $1,000
Q4 2019 Feb 13, 2020	BUY	$7.23 - $8.55 $7,439 - $8,797	1,029 Added 588.0%	1,204 $10,000
Q3 2019 Oct 17, 2019	SELL	$6.42 - $9.0 $911 - $1,278	-142 Reduced 44.79%	175 $1,000
Q2 2019 Aug 05, 2019	SELL	$6.1 - $8.78 $41,272 - $59,405	-6,766 Reduced 95.52%	317 $2,000
Q1 2019 Apr 16, 2019	BUY	$7.6 - $9.4 $14,949 - $18,489	1,967 Added 38.45%	7,083 $57,000
Q4 2018 Jan 17, 2019	BUY	$6.51 - $10.19 $10,318 - $16,151	1,585 Added 44.89%	5,116 $38,000
Q3 2018 Nov 02, 2018	BUY	$8.24 - $11.0 $29,095 - $38,841	3,531 New	3,531 $0

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.